» Articles » PMID: 34093820

MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells

Overview
Journal J Cancer
Specialty Oncology
Date 2021 Jun 7
PMID 34093820
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy plays an important role in the treatment of leukemia. Multidrug resistance (MDR) induced by chemotherapy always leads to treatment failure and disease recurrence. MicroRNAs (miRNAs) have been verified as crucial components in carcinogenesis, including chemo-resistance of tumor cells, which has not been fully understood. In this study, we aimed to identify the potential candidate miRNA, miR-1246, and reveal its regulatory role in chemo-resistance of leukemia cells. Candidate miRNAs were selected by microarray analysis, screened by bioinformatics tools and verified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Chemo-resistant phenotypes, including cell viability, apoptosis, adriamycin (ADM) efflux and oncogenicity of leukemia cells following transfected with miR-1246 mimics or inhibitor were checked with or without ADM treatment to make clear the relationship between miR-1246 and chemo-resistance. RT-qPCR, western blot and dual luciferase reporter assay were performed to measure the expression of related genes and address the potential regulatory mechanism of miR-1246 in chemo-resistance. The expression of miR-1246 was significantly higher in chemo-resistant leukemia K562/ADM cells, HL-60/RS cells and recurrent primary leukemia cells. Loss of miR-1246 inhibited proliferation, induced apoptosis, altered cell cycle distribution, inhibited ADM efflux in chemo-resistant leukemia cells, while overexpression of miR-1246 showed the opposite role in chemo-sensitive leukemia cells. Both bioinformatics prediction and luciferase assay indicated that AXIN2 and glycogen synthase kinase 3 beta (GSK-3β) were the direct targets of miR-1246 in leukemia cells. Inhibition of miR-1246 could up-regulate AXIN2 and GSK-3β and inactivate Wnt/β-catenin pathway, accompanied with inhibiting the expression of β-catenin and further influencing the expression of P-glycoprotein (P-gp) in the chemo-resistant leukemia cells. Chemo-resistant ability of MDR leukemia cells is attenuated by loss of miR-1246 via negatively regulating AXIN2 and GSK-3β to inactivate Wnt/β-catenin pathway and suppress P-gp expression, these mean that targeting miR-1246-AXIN2/GSK-3β-Wnt/β-catenin axis may be beneficial to overcome the chemo-resistance in relapse and refractory leukemia patients.

Citing Articles

MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.

Lu X, Jin H Front Pharmacol. 2024; 15:1486783.

PMID: 39679367 PMC: 11638538. DOI: 10.3389/fphar.2024.1486783.


Exosome-Mediated Paracrine Signaling Unveils miR-1246 as a Driver of Aggressiveness in Fusion-Negative Rhabdomyosarcoma.

Ramadan F, Saab R, Ghamloush F, Khoueiry R, Herceg Z, Gomez L Cancers (Basel). 2024; 16(9).

PMID: 38730605 PMC: 11083369. DOI: 10.3390/cancers16091652.


miR-1246-overexpressing exosomes improve UVB-induced photoaging by activating autophagy via suppressing GSK3β.

Gao W, Yuan L, Zhang Y, Huang F, Ai C, Lv T Photochem Photobiol Sci. 2024; 23(5):957-972.

PMID: 38613601 DOI: 10.1007/s43630-024-00567-w.


Role of Non-Coding RNAs in Diagnosis, Prediction and Prognosis of Multiple Myeloma.

Dubaj M, Bigosinski K, Dembowska A, Mlak R, Szudy-Szczyrek A, Malecka-Massalska T Cancers (Basel). 2024; 16(5).

PMID: 38473390 PMC: 10931522. DOI: 10.3390/cancers16051033.


CADM1 impairs the effect of miR-1246 on promoting cell cycle progression in chemo-resistant leukemia cells.

Xie B, Zhao L, Zhang Z, Zhou C, Tian Y, Kang Y BMC Cancer. 2023; 23(1):955.

PMID: 37814227 PMC: 10561441. DOI: 10.1186/s12885-023-11458-1.


References
1.
Chai S, Ng K, Tong M, Lau E, Lee T, Chan K . Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 2016; 64(6):2062-2076. DOI: 10.1002/hep.28821. View

2.
Jaiswal R, Luk F, Gong J, Mathys J, Grau G, Bebawy M . Microparticle conferred microRNA profiles--implications in the transfer and dominance of cancer traits. Mol Cancer. 2012; 11:37. PMC: 3499176. DOI: 10.1186/1476-4598-11-37. View

3.
Bernardo B, Ooi J, Lin R, McMullen J . miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015; 7(13):1771-92. DOI: 10.4155/fmc.15.107. View

4.
Ghodousi E, Rahgozar S . MicroRNA-326 and microRNA-200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia. J Cell Biochem. 2018; 119(7):6024-6032. DOI: 10.1002/jcb.26800. View

5.
Song B, Tang Y, Zhang W, Wan C, Chen Y, Zhang L . MiR-143 regulates proliferation and apoptosis of myelocytic leukemia cell HL-60 via modulating ERK1. Eur Rev Med Pharmacol Sci. 2018; 22(11):3333-3341. DOI: 10.26355/eurrev_201806_15153. View